Trial Profile
Phase Ib Study of a Monoclonal Antibody to OX40 (MEDI0562) Administered Prior to Surgical Resection in Patients With Head and Neck Squamous Cell Carcinoma or Melanoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 16 Aug 2023
Price :
$35
*
At a glance
- Drugs Tavolimab (Primary)
- Indications Head and neck cancer; Malignant melanoma; Squamous cell cancer
- Focus Pharmacodynamics
- 09 Aug 2023 Planned End Date changed from 1 Dec 2024 to 1 Dec 2025.
- 09 Aug 2023 Planned primary completion date changed from 1 Jul 2023 to 1 Jun 2025.
- 13 Jul 2022 Planned primary completion date changed from 1 Jul 2022 to 1 Jul 2023.